Wednesday, August 26, 2026

Takeda to Discontinue GAMMAGARD S/D by End of 2027, Inventory to Deplete Through 2028

Takeda Pharmaceutical announced plans to discontinue GAMMAGARD S/D production by December 31, 2027, with remaining inventory available until depleted or expired. The immunoglobulin therapy phase-out signals a portfolio shift as the Japanese pharma giant realigns its product offerings in the competitive immune deficiency treatment market.

Takeda to Discontinue GAMMAGARD S/D by End of 2027, Inventory to Deplete Through 2028
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Takeda Pharmaceutical will discontinue GAMMAGARD S/D by December 31, 2027, the company announced, with existing inventory to remain available until stocks expire or deplete in 2028.

The immunoglobulin therapy has treated primary immunodeficiency disorders for decades. Takeda cited portfolio optimization as the driver behind the phase-out decision.

GAMMAGARD S/D competes in a crowded immunoglobulin market dominated by CSL Behring, Grifols, and Octapharma. The global immune globulin market reached $12.8 billion in 2023, growing at 6.2% annually as demand rises for rare disease treatments.

Takeda's move follows a broader trend of pharma companies exiting legacy products to focus on higher-margin therapies. The company has invested heavily in rare disease and oncology pipelines, acquiring Shire Pharmaceuticals for $62 billion in 2019 to expand its immunology portfolio.

Investors reacted neutrally to the announcement, viewing it as a minor portfolio adjustment rather than a material revenue impact. GAMMAGARD S/D represents a small fraction of Takeda's $30.4 billion annual revenue, with newer immunoglobulin products like CUVITRU and HYQVIA driving growth in the segment.

Patients currently on GAMMAGARD S/D therapy will need to transition to alternative treatments before the 2028 depletion deadline. Physicians typically require 6-12 months to safely switch immunoglobulin therapies, giving adequate time for migration.

Takeda faces pricing pressure across its immunoglobulin line as insurers push back on therapy costs exceeding $100,000 annually per patient. Biosimilar competition remains limited in this category due to complex manufacturing processes.

The discontinuation aligns with Takeda's 2024 strategic plan to streamline operations and divest non-core assets. The company sold its over-the-counter portfolio and diabetes drug pipeline to concentrate on rare diseases, gastroenterology, and plasma-derived therapies.

Market analysts expect minimal impact on Takeda's share price, with attention focused on the company's pipeline drugs in inflammatory bowel disease and hemophilia. The stock trades at 13.2x forward earnings, below the pharma sector average of 15.8x.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleYahoo Finance· January 22, 2026
    Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com